Akinyinka Ajelabi, MD
Critical Care Medicine · Kingwood, TXNPI 1841227808
Payments from drug & device makers
Across 812 payments — averaging $134.32 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$94K
- Inspire Medical Systems, Inc.$3K
- AstraZeneca$2K
- Itamar Medical Inc$1K
- Electromed, Inc.$968
- Sanofi$940
- plus $7K from 35 others
What the payments were for
- Consulting fees$7501%
- Speaking & faculty fees$88,62581%
- Travel & lodging$2,0382%
- Food & beverage$17,21216%
- Education$4410%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| GSK | 266 | $93,992 |
| Inspire Medical Systems, Inc. | 76 | $3,174 |
| AstraZeneca | 68 | $1,888 |
| Itamar Medical Inc | 4 | $1,099 |
| Electromed, Inc. | 51 | $968 |
| Sanofi | 40 | $940 |
| Regeneron Healthcare Solutions, Inc. | 41 | $896 |
| Jazz Pharmaceuticals Inc. | 22 | $729 |
| Boehringer Ingelheim | 32 | $629 |
| Philips North America LLC | 33 | $532 |
| Mylan Specialty L.p. | 21 | $454 |
| Takeda Pharmaceuticals U.S.A., Inc. | 18 | $432 |
| Mallinckrodt Hospital Products Inc. | 13 | $354 |
| Baxter Healthcare | 10 | $271 |
| Insmed, Inc. | 12 | $248 |
| Verona Pharma, Inc. | 12 | $237 |
| Viatris Specialty LLC | 11 | $230 |
| Harmony Biosciences LLC | 6 | $212 |
| Axsome Therapeutics, Inc. | 7 | $203 |
| Pulmonx Corporation | 6 | $200 |
| AbbVie(2 entities) | 8 | $171 |
| Sunovion Pharmaceuticals Inc. | 12 | $157 |
| Medtronic | 1 | $154 |
| Pfizer | 5 | $108 |
| Johnson & Johnson | 5 | $94 |
| Paratek Pharmaceuticals, Inc. | 4 | $69 |
| Shionogi Inc | 3 | $68 |
| Gilead | 3 | $55 |
| Amgen | 2 | $55 |
| Genentech USA, Inc. | 3 | $54 |
| 3b Medical, Inc. | 1 | $49 |
| Vifor Pharma, Inc. | 2 | $48 |
| Merck | 3 | $47 |
| Lilly USA, LLC | 2 | $47 |
| Grifols USA, LLC | 2 | $46 |
| Inogen, Inc. | 1 | $37 |
| Circassia Inc. | 2 | $33 |
| Avadel CNS Pharmaceuticals, LLC | 1 | $28 |
| ZOLL Respicardia, Inc. | 1 | $27 |
| Phadia US Inc. | 1 | $21 |
| Biomerieux Inc | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- TRELEGY ELLIPTA$35,027
- AREXVY$14,625
- ANORO ELLIPTA$7,303
- Inspire$1,423
- WatchPATONE$750
- Inspire Upper Airway Stimulation System$574
- BREZTRI$242
- WatchPat$229
- VenaSeal$154
- FASENRA$129
- DUPIXENT$122
- LOKELMA$109
How this compares
$109,066 in reported general payments places this provider in the 95th percentile of 507 critical care medicine providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OfevNintedanib Esylate | 31 | $429,026 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 531 | $428,788 |
| Dupixent PenDupilumab | 20 | $78,486 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 96 | $73,132 |
| Dupixent SyringeDupilumab | 12 | $44,385 |
| Spiriva RespimatTiotropium Bromide | 26 | $20,091 |
| Breo ElliptaFluticasone/Vilanterol | 37 | $17,857 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 22 | $11,885 |
| Incruse ElliptaUmeclidinium Bromide | 24 | $10,413 |
| EliquisApixaban | 17 | $10,060 |
| BelsomraSuvorexant | 12 | $5,413 |
| Atrovent HfaIpratropium Bromide | 11 | $5,185 |
| BreynaBudesonide/Formoterol Fumarate | 21 | $5,005 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 226 | $4,781 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 31 | $4,384 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta, Incruse Ellipta | $93,992 | $468,942614 claims |
| Boehringer IngelheimOfev, Spiriva Respimat | $629 | $449,11757 claims |
| AstraZenecaBreztri Aerosphere, Symbicort | $1,888 | $77,408114 claims |
| PfizerEliquis | $108 | $10,06017 claims |
| MerckBelsomra | $47 | $5,41312 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 507 critical care medicine providers in Texas.
Other critical care medicine in Kingwood
- Cynthia ZamoraSan Antonio$6.4M
- Rishi RajLubbock$1.9M
- Carlo HatemEl Paso$1.6M
- Deepa GoturHouston$1.1M
- Matt KhoshnevisHouston$759K
- Sean GilbeyAustin$723K
- Rodeo AbrencilloHouston$616K
- Jeffrey DellavolpeFort Sam Houston$466K
- Steven DavidoffPlano$364K
- Matthew AndersonAustin$314K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.